Joby Collaborates With L3Harris to Pursue Defense Applications for Autonomous Hybrid VTOL Aircraft
The collaboration leverages Joby's existing commercial aircraft development program and leading manufacturing capabilities, combined with L3Harris' proven expertise on platform missionization including sensors, effectors, communication and collaborative autonomy. Flight testing is expected to start this fall with the companies planning to perform operational demonstrations during government exercises in 2026.
'The next-generation of vertical lift technology enables long-range, crewed-uncrewed teaming for a range of missions,' said Jon Rambeau, President, Integrated Mission Systems, L3Harris. 'We share a vision with Joby to deliver urgently-required innovation by missionizing VTOL aircraft for defense needs.'
JoeBen Bevirt, founder and CEO, Joby Aviation, added: 'We have worked closely with the Department of Defense over the past decade to give them a front row seat to the development of our dual-purpose technologies, and we're now ready to demonstrate and deploy it. Our country depends on companies like ours moving at pace, and we have the team, the technology and the platform to do just that.'
Joby is actively developing a gas turbine hybrid powertrain for its current S4 aircraft platform and has demonstrated aircraft-level autonomy following its acquisition of the autonomy division of Xwing in June 2024. It has previously demonstrated under government contract that its platform can be hybridized to deliver longer-ranges, showcasing an industry-first 561 mile hydrogen-electric hybrid flight in June 2024.
About Joby
Joby Aviation, Inc. (NYSE:JOBY) is a California-based transportation company developing an all-electric, vertical take-off and landing air taxi. Joby intends to both operate its fast, quiet, and convenient air taxi service in cities around the world and sell its aircraft to other operators and partners. To learn more, visit www.jobyaviation.com.
About L3Harris Technologies
L3Harris Technologies is the Trusted Disruptor in the defense industry. With customers' mission-critical needs always in mind, our employees deliver end-to-end technology solutions connecting the space, air, land, sea and cyber domains in the interest of national security. Visit L3Harris.com for more information.
Forward Looking Statements
This release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the development and performance of Joby's aircraft and L3Harris' missionization capabilities, including the potential applications for a gas turbine hybrid VTOL aircraft and related autonomous capabilities; each of Joby's and L3Harris' business plan, objectives, goals and market opportunity; plans for, and potential benefits of, our respective strategic partnerships; and our current expectations relating to our respective businesses, financial condition, results of operations, and prospects. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as 'anticipate', 'estimate', 'expect', 'project', 'plan', 'intend', 'believe', 'may', 'will', 'should', 'can have', 'likely' and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: the ability to produce aircraft that meet performance expectations in the volumes and on the timelines that Joby projects; L3Harris' ability to missionize aircraft as required government customers and to accurately project the cost and timelines for such missionization; the ability to secure additional contracts with the Department of Defense or other U.S. governmental agencies cannot be guaranteed; the competitive environment in which Joby and L3Harris operate; Joby's future capital needs; our ability to adequately protect and enforce our respective intellectual property rights; Joby's ability to effectively respond to evolving regulations and standards relating to aircraft; our reliance on third-party suppliers and service partners; uncertainties related to our estimates of the size of the market for our service and future revenue opportunities; our customers' ability to modify or terminate contracts; and other important factors discussed in the sections titled 'Risk Factors' in Joby's and L3Harris' Annual Reports on Form 10-K, filed with the Securities and Exchange Commission (the 'SEC') on February 27, 2025 and February 14, 2025, respectively, Joby's and L3Harris' Quarterly Reports on Form 10-Q filed with the SEC on May 8, 2025 and April 24, 2025, respectively, and in future filings and other reports either Joby or L3Harris file with or furnish to the SEC. Any such forward-looking statements represent Joby's or L3Harris' management's estimates and beliefs as of the date of this release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Agora, Inc. to Report Second Quarter 2025 Financial Results on August 18, 2025
SANTA CLARA, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ: API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the second quarter ended June 30, 2025 after the close of U.S. markets on August 18, 2025. Agora, Inc. will host a conference call to discuss the financial results at 6 p.m. Pacific Time / 9 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 2Q 2025 Financial Results The call will be available at Investors who want to hear the call should log on at least 15 minutes prior to the broadcast. Participants may register for the call with the link below. Please visit Agora, Inc.'s investor relations website at on August 18, 2025 to view the earnings release and accompanying slides prior to the conference call. About Agora, Inc. Agora, Inc. is the holding company of two independent businesses, Agora and Shengwang. Headquartered in Santa Clara, California, Agora is a pioneer and global leader in conversational AI and Real-Time Engagement Platform-as-a-Service (PaaS), providing developers with simple, flexible, and powerful application programming interfaces, or APIs, to embed real-time conversational AI, video, voice, chat and interactive streaming into their applications. Headquartered in Shanghai, China, Shengwang is a pioneer and leading conversational AI and Real-Time Engagement PaaS provider in the China market. For more information on Agora, please visit: more information on Shengwang, please visit: CONTACT: Investor Contact: investor@ Media Contact: press@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
23 minutes ago
- Business Wire
Tempus Reports Second Quarter 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. Revenue increased 89.6% year-over-year to $314.6 million in the second quarter Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services revenue increased 35.7% year-over-year to $72.8 million, led by Insights (data licensing), which grew 40.7% year-over-year Quarterly gross profit was $195.0 million, a 158.3% year-over-year increase Issued $750 million of 0.75% convertible senior notes that will drive significant interest expense and cash savings Increasing full year 2025 revenue guidance to $1.26 billion, along with positive adjusted EBITDA of $5 million, a $110 million improvement over 2024 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes which grew 30% in the quarter, as we delivered more than 212,000 NGS tests. Combined with our continued leadership in AI and progress toward building the largest foundation model in oncology, 'we're hitting our stride' as we approach our 10th anniversary.' Second Quarter Summary Results Quarterly revenue increased 89.6% year-over-year to $314.6 million. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% compared to the second quarter of 2024. Oncology testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9% year-over-year with approximately 26% volume growth versus 20% last quarter. Hereditary testing (Ambry genetics) contributed $97.3 million of revenue, up 33.6% year-over-year on a pro forma basis 1 with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million in the second quarter, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Generated $195.0 million in quarterly gross profit, reflecting a 158.3% increase year-over-year. Improvement in reported net loss of ($42.8 million) in the second quarter of 2025, including fair value gains of $37.8 million related to our marketable equity securities and stock compensation and employer payroll tax related to stock-based compensation of ($24.3) million, compared to a net loss of ($552.2 million) in the second quarter of 2024. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. Second Quarter and Recent Operational Highlights Strengthened Financial Flexibility: Just after quarter end, we completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing our balance sheet and allowing us to replace a portion of the existing term loan with a significantly lower interest debt instrument. We also ended the quarter with $293.0 million in cash and marketable securities, an improvement of ~$70 million over last quarter. Expanded AI-Powered Clinical Tools: Extended Tempus Next™ care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. In addition, Tempus One™, our generative AI clinical assistant, was integrated into leading electronic health record (EHR) systems to enhance physician workflows and point-of-care insights. Advanced MRD and monitoring: Introduced Tempus xM™ for treatment and response monitoring (TRM), a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors, providing clinicians with actionable, real-time insights. We also expanded our exclusive collaboration with Personalis to include colorectal cancer as the fourth indication under the NeXT Personal® MRD commercial partnership. Reached new database milestone: Through more than 4,500 integrations, we are now connected to more than 40 million clinical patient records, with ~9 million de-identified and ingested, spanning ~1.1 billion healthcare documents, a significant percentage of which are connected to the ~4 million samples we have sequenced. As a result, our database now stands at >350 petabytes of connected clinical and molecular data. Approaching 10-Year anniversary: As we near Tempus' 10-year anniversary, we're reflecting on a decade of innovation and collaboration which now spans more than 2,000 publications including ~700 peer reviewed articles and ~180 oral presentations. ____________ (1) Not meaningful due to the impact of stock compensation expense and employer payroll tax related to stock-based compensation associated with the initial public offering in June 2024 Expand Financial Outlook and Guidance Tempus is increasing its guidance and now expects full year 2025 revenue of approximately $1.26 billion for the consolidated business, which represents approximately 82% annual growth, and Adjusted EBITDA of $5 million for full year 2025, an improvement of approximately $110 million over 2024. For additional information on the quarter, including a letter from our CEO and CFO, please visit our investors relations site at Webcast and Conference Call Information A conference call and webcast will be held on Friday, August 8, 2025 at 8:00 a.m. Eastern Time. Interested parties may access details using: Conference ID: 7005219 Domestic Dial-in Number: (800) 715 - 9871 International Dial-in Number: (646) 307 - 1963 Live webcast: The webcast may be accessed on the company's investor relations website at For those unable to listen to the live webcast, a recording will be made available on the company's website after the event and will be accessible for one year. Visit the investor relations website to find the company's latest deck, and commentary on the quarter and year by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Non-GAAP Financial Measures In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures. Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the 'stock-based compensation adjustments'). Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue. Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to our IPO. Non-GAAP loss from operations is defined as loss from operations, adjusted to exclude (i) stock-based compensation expense, (ii) employer payroll tax related to stock-based compensation expense, (iii) acquisition-related expenses, (iv) franchise taxes related to our IPO, and (v) amortization of intangibles due to acquisition. Non-GAAP net loss is defined as net loss, adjusted to exclude (i) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (ii) stock-based compensation expense, (iii) employer payroll tax related to stock-based compensation expense, (iv) acquisition-related expenses, (v) amortization of intangibles due to acquisition, (vi) losses on equity method investments, (vii) (benefit from) provision for income taxes, (viii) the payment of $2.3 million of our Series G-4 convertible preferred stock in connection with the initial public offering (the "G-4 Special Payment"), (ix) franchise taxes related to our IPO, and (x) amortization of deferred other income from our IP License Agreement with SB Tempus. Non-GAAP net loss per share is defined as non-GAAP net loss divided by weighted average common shares outstanding, basic and diluted. Adjusted EBITDA is defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses on equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) stock-based compensation expense, (viii) employer payroll tax related to stock-based compensation expense, (ix) acquisition related expenses, (x) the G-4 Special Payment, (xi) amortization of deferred other income from our IP License Agreement with SB Tempus, and (xii) franchise taxes related to our IPO. Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus' business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures. Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to EBITDA and Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus' forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net income (loss) and the respective reconciliations. These forecasted items are not within Tempus' control, may vary greatly between periods, and could significantly impact future financial results. Other Key Metrics Total Remaining Contract Value (TCV) is equal to the total potential value of signed contracts and assumes the exercise of all contract options, all discretionary opt-ins, and no early termination. Remaining TCV excludes any revenue recognized to date on these contracts or any future adjustments made to the contractual value as a result of amendments or terminations. Net Revenue Retention compares the annual Insights product revenue generated from all customers that made an Insights purchase in one year to the annual Insights product revenue generated from the same cohort of customers in the subsequent year. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus' expected financial results for full year 2025; expectations concerning the interest and cost savings associated with our convertible senior notes; and other statements that are not historical fact. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus' ability to realize the expected benefits of the acquisition of Ambry Genetics and Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('the SEC') on February 24, 2025, as supplemented by Tempus' Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 8, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. (1) Includes related party revenue of $15,908, $108, $16,539, $215 for the three and six months ended June 30, 2025 and 2024, respectively. Expand Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except share and per share amounts) December 31, 2024 Assets Current Assets Cash and cash equivalents $ 186,310 $ 340,954 Accounts receivable, net of allowances of $1,545 and $1,141 at June 30, 2025 and December 31, 2024, respectively 266,284 154,819 Inventory 47,600 38,386 Related party asset 2,535 — Prepaid expenses and other current assets 36,476 26,135 Marketable equity securities 104,996 107,309 Total current assets $ 644,201 $ 667,603 Property and equipment, net 92,563 58,056 Goodwill 325,793 73,343 Intangible assets, net 387,564 11,716 Investments and other assets 16,669 8,305 Investment in joint venture 95,718 91,450 Related party asset, less current portion 22,465 — Operating lease right-of-use assets 38,651 14,762 Restricted cash 1,741 881 Total Assets $ 1,625,365 $ 926,116 Liabilities, Convertible redeemable preferred stock, and Stockholders' equity Current Liabilities Accounts payable 79,323 53,804 Related party payable 25,000 — Accrued expenses 165,903 130,407 Deferred revenue (1) 100,477 75,981 Deferred other income 15,955 15,955 Other current liabilities 16,554 6,964 Operating lease liabilities 9,381 6,459 Accrued data licensing fees 5,567 1,500 Total current liabilities $ 418,160 $ 291,070 Operating lease liabilities, less current portion 45,866 26,199 Convertible promissory note 226,342 168,192 Other long-term liabilities 9,508 15,980 Revolving credit facility 100,000 — Interest payable 5,084 70,450 Long-term debt, net 471,663 267,244 Deferred other income, less current portion 15,955 23,932 Deferred revenue, less current portion 23,225 6,710 Total Liabilities $ 1,315,803 $ 869,777 Expand (1) Includes related party deferred revenue of $36,685 and $0 as of June 30, 2025 and December 31, 2024, respectively. Expand Commitments and contingencies (Note 8) Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively, no shares issued and outstanding at June 30, 2025 and December 31, 2024; aggregate liquidation preference of $0 at June 30, 2025 and December 31, 2024, respectively $ — $ — Stockholders' equity Class A Voting Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 168,580,827 and 157,076,972 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 17 16 Class B Voting Common Stock, $0.0001 par value, 5,500,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 5,043,789 issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1 1 Non-voting Common Stock, $0.0001 par value, no shares authorized at June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding at June 30, 2025, and December 31, 2024, respectively — — Treasury Stock, 145,466 shares at June 30, 2025 and December 31, 2024, at cost (3,602 ) (3,602 ) Additional Paid-In Capital 2,566,412 2,210,664 Accumulated Other Comprehensive Income 8,448 94 Accumulated deficit (2,261,714 ) (2,150,834 ) Total Stockholders' equity $ 309,562 $ 56,339 Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity $ 1,625,365 $ 926,116 Expand Tempus AI, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands, except per share amounts) Six Months Ended June 30, 2025 2024 Operating activities Net loss $ (110,880 ) $ (616,955 ) Adjustments to reconcile net loss to net cash used in operating activities Change in fair value of warrant liability $ — $ (900 ) Stock-based compensation 45,429 488,313 Gain on warrant exercise — (173 ) Gain on marketable equity securities (6,007 ) (2,541 ) Deferred income taxes (46,216 ) — Losses from equity method investments 3,983 — Amortization of original issue discount 1,169 691 Amortization of deferred financing fees 332 255 Change in fair value of contingent consideration — 165 Change in fair value of holdback liability 312 — Amortization of warrant contract asset — 2,422 Depreciation and amortization 48,385 18,348 Provision for bad debt expense 625 327 Change in fair value of warrant asset — 7,700 Non-cash operating lease costs 4,573 3,252 Minimum accretion expense 108 92 PIK interest added to principal 7,157 4,366 Change in assets and liabilities Accounts receivable (49,155 ) (23,971 ) Inventory 1,974 (3,845 ) Prepaid expenses and other current assets (188 ) (12,409 ) Investments and other assets (11,073 ) 1,294 Accounts payable 7,025 (33,371 ) Deferred revenue (1) 36,836 (28,669 ) Deferred other income (7,977 ) — Accrued data licensing fees 3,957 (2,749 ) Accrued expenses & other 6,991 (2,805 ) Interest payable 7,122 7,287 Operating lease liabilities (5,942 ) (4,582 ) Net cash used in operating activities $ (61,460 ) $ (198,458 ) Investing activities Purchases of property and equipment $ (9,588 ) $ (14,116 ) Proceeds from sale of marketable equity securities 8,316 23,098 Business combinations, net of cash acquired (Note 4) (380,762 ) — Purchases of capitalized software (3,295 ) — Net cash (used in) provided by investing activities $ (385,329 ) $ 8,982 Expand (1) Includes increase in related party deferred revenue of $36,685 and $0 as of June 30, 2025 and December 31, 2024, respectively. Expand Financing activities Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions $ — $ 381,951 Tax withholding related to net share settlement of restricted stock units — (69,918 ) Issuance of Series G-5 Preferred Stock — 199,750 Payment of deferred offering costs — (2,714 ) Dividends paid — (5,625 ) Proceeds from revolving credit facility, net of original issue discount 98,000 — Proceeds from long-term debt, net of original issue discount 196,000 — Payment of deferred financing fees (958 ) — Payment of indemnity holdback related to acquisition — (813 ) Net cash provided by financing activities $ 293,042 $ 502,631 Effect of foreign exchange rates on cash $ (37 ) $ (90 ) Net (decrease) increase in Cash, Cash Equivalents and Restricted Cash $ (153,784 ) $ 313,065 Cash, cash equivalents and restricted cash, beginning of period 341,835 166,607 Cash, cash equivalents and restricted cash, end of period $ 188,051 $ 479,672 Cash, Cash Equivalents and Restricted Cash are Comprised of: Cash and cash equivalents $ 186,310 $ 478,811 Restricted cash and cash equivalents 1,741 861 Total cash, cash equivalents and restricted cash $ 188,051 $ 479,672 Supplemental disclosure of cash flow information Cash paid during the year for interest $ 23,980 $ 13,921 Cash paid for income taxes $ 136 $ 89 Supplemental disclosure of noncash investing and financing activities Dividends payable $ — $ 5,487 Purchases of property and equipment, accrued but not paid $ 6,863 $ 1,108 Redemption of convertible promissory note $ 14,338 $ 12,476 Non-voting common stock issued in connection with business combinations $ — $ 344 Deferred financing fees, accrued but not yet paid $ 545 $ — Deferred offering costs, accrued but not yet paid $ 95 $ 6,051 Operating lease liabilities arising from obtaining right-of-use assets $ 606 $ — Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering $ — $ 1,348,809 Taxes related to net share settlement of restricted stock units not yet paid $ — $ 164 Reclassification of deferred offering costs to additional paid-in capital upon initial public offering $ — $ 12,347 Class A Voting Common Stock issued in connection with business combinations $ 310,320 $ — Issuance of Series G-3 Preferred Stock $ — $ 3,809 Issuance of Series G-4 Preferred Stock $ — $ 611 Convertible promissory note principal reset due to amendment $ 72,488 $ — Expand Tempus AI, Inc. (Unaudited) (in thousands, except percentages and per share amounts) Genomics Gross Profit & Gross Margin Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Genomics revenue $ 241,843 $ 112,324 $ 435,647 $ 214,893 Cost of revenues, genomics 99,756 68,324 184,539 121,159 Gross profit, genomics $ 142,087 $ 44,000 $ 251,108 $ 93,734 Stock-based compensation expense 1,420 11,327 2,455 11,327 Employer payroll tax related to stock-based compensation 254 136 302 136 Non-GAAP gross profit, genomics $ 143,761 $ 55,463 $ 253,865 $ 105,197 Genomics gross margin 58.8 % 39.2 % 57.6 % 43.6 % Stock-based compensation expense 0.6 % 10.1 % 0.6 % 5.3 % Employer payroll tax related to stock-based compensation 0.1 % 0.1 % 0.1 % 0.1 % Non-GAAP gross margin, genomics 59.4 % 49.4 % 58.3 % 49.0 % Expand Data and Services Gross Profit & Gross Margin Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Data and services revenue $ 72,792 $ 53,645 $ 134,725 $ 96,896 Cost of revenues, data and services 19,840 22,132 35,591 37,420 Gross profit, data and services $ 52,952 $ 31,513 $ 99,134 $ 59,476 Stock-based compensation expense 693 7,229 1,304 7,229 Employer payroll tax related to stock-based compensation 114 119 158 119 Non-GAAP gross profit, data and services $ 53,759 $ 38,861 $ 100,596 $ 66,824 Gross margin, data and services 72.7 % 58.7 % 73.6 % 61.4 % Stock-based compensation expense 1.0 % 13.5 % 1.0 % 7.5 % Employer payroll tax related to stock-based compensation 0.2 % 0.2 % 0.1 % 0.1 % Non-GAAP gross margin, data and services 73.9 % 72.4 % 74.7 % 69.0 % Expand Total Gross Profit & Gross Margin Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net revenue $ 314,635 $ 165,969 $ 570,372 $ 311,789 Cost of revenues 119,596 90,456 220,130 158,579 Gross profit $ 195,039 $ 75,513 $ 350,242 $ 153,210 Stock-based compensation expense 2,113 18,556 3,759 18,556 Employer payroll tax related to stock-based compensation 369 255 460 255 Non-GAAP gross profit $ 197,521 $ 94,324 $ 354,461 $ 172,021 Gross margin 62.0 % 45.5 % 61.4 % 49.1 % Stock-based compensation expense 0.7 % 11.2 % 0.7 % 6.0 % Employer payroll tax related to stock-based compensation 0.1 % 0.2 % 0.1 % 0.1 % Non-GAAP gross margin 62.8 % 56.8 % 62.1 % 55.2 % Expand Operating Expenses Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Technology research and development $ 34,482 $ 77,908 $ 67,873 $ 104,975 Stock-based compensation expense 3,285 50,434 6,604 50,434 Employer payroll tax related to stock-based compensation 495 1,248 756 1,248 Non-GAAP technology research and development $ 30,702 $ 26,226 $ 60,513 $ 53,293 Research and development $ 41,619 $ 68,025 $ 77,493 $ 92,365 Stock-based compensation expense 2,335 42,233 4,317 42,233 Employer payroll tax related to stock-based compensation 235 676 411 676 Non-GAAP research and development $ 39,049 $ 25,116 $ 72,765 $ 49,456 Selling, general and administrative $ 180,712 $ 463,072 $ 335,339 $ 542,636 Stock-based compensation expense 14,722 377,090 30,749 377,090 Employer payroll tax related to stock-based compensation 774 2,582 5,499 2,582 Acquisition related expenses 1,992 — 5,521 — Amortization of intangibles due to acquisition 16,771 — 27,927 — Franchise taxes related to IPO 1,647 — 1,647 — Non-GAAP selling, general and administrative $ 144,806 $ 83,400 $ 263,996 $ 162,964 Operating expenses $ 256,813 $ 609,005 $ 480,705 $ 739,976 Stock-based compensation expense 20,342 469,757 41,670 469,757 Employer payroll tax related to stock-based compensation 1,504 4,506 6,666 4,506 Acquisition related expenses 1,992 — 5,521 — Amortization of intangibles due to acquisition 16,771 — 27,927 — Franchise taxes related to IPO 1,647 — 1,647 — Non-GAAP operating expenses $ 214,557 $ 134,742 $ 397,274 $ 265,713 Expand Earnings per Share Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss $ (42,843 ) $ (552,212 ) $ (110,880 ) $ (616,955 ) Fair value changes (1) (37,546 ) 4,870 (5,696 ) 4,280 Stock-based compensation expense 22,455 488,313 45,429 488,313 Employer payroll tax related to stock-based compensation 1,873 4,762 7,126 4,762 Acquisition related expenses (2) 1,992 — 5,521 — Amortization of intangibles due to acquisition 16,771 — 27,927 — Losses on equity method investments 2,100 — 3,983 — Provision for (benefit from) income taxes 212 95 (45,968 ) 106 G-4 Special Payment — 2,250 — 2,250 Franchise taxes related to IPO 1,647 — 1,647 — Amortization of technology license (3,988 ) — (7,977 ) — Non-GAAP net loss $ (37,327 ) $ (51,922 ) $ (78,888 ) $ (117,244 ) Non-GAAP net loss per share $ (0.22 ) $ (0.63 ) $ (0.46 ) $ (1.61 ) Weighted average common shares outstanding, basic and diluted 173,381 82,325 171,960 72,930 Expand (1) Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities. (2) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and six months ended June 30, 2025. Expand Adjusted EBITDA Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss $ (42,843 ) $ (552,212 ) $ (110,880 ) $ (616,955 ) Interest income (1,093 ) (1,718 ) (2,906 ) (2,749 ) Interest expense 21,579 13,295 39,582 26,533 Depreciation 8,347 6,415 16,230 12,684 Amortization 19,685 2,744 32,155 5,664 Provision for (benefit from) income taxes 212 95 (45,968 ) 106 EBITDA $ 5,887 $ (531,381 ) $ (71,787 ) $ (574,717 ) Losses on equity method investments 2,100 — 3,983 — Fair value changes (1) (37,546 ) 4,870 (5,696 ) 4,280 Stock-based compensation expense 22,455 488,313 45,429 488,313 Employer payroll tax related to stock-based compensation 1,873 4,762 7,126 4,762 Acquisition related expenses (2) 1,992 — 5,521 — G-4 Special Payment — 2,250 — 2,250 Amortization of technology license (3,988 ) — (7,977 ) — Franchise taxes related to IPO 1,647 — 1,647 — Expand (1) Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities. (2) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions of during the three and six months ended June 30, 2025. Expand Loss from Operations Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Loss from operations $ (61,774 ) $ (533,492 ) $ (130,463 ) $ (586,766 ) Stock-based compensation expense 22,455 488,313 45,429 488,313 Employer payroll tax related to stock-based compensation 1,873 4,762 7,126 4,762 Acquisition related expenses (1) 1,992 — 5,521 — Franchise taxes related to IPO 1,647 — 1,647 — Amortization of intangibles due to acquisition 16,771 — 27,927 — Non-GAAP loss from operations $ (17,036 ) $ (40,417 ) $ (42,813 ) $ (93,691 ) Expand (1) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and six months ended June 30, 2025. Expand
Business Wire
23 minutes ago
- Business Wire
Emera Reports 2025 Second Quarter Financial Results
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera Inc. ('Emera') (TSX/NYSE: EMA) reported financial results for the second quarter and year-to-date 2025. Highlights Emera delivers 49% quarterly adjusted earnings per share 1 ('EPS') growth with second quarter adjusted EPS 1 of $0.79 and reported EPS of $0.45. In the first half of 2025, teams across Emera successfully deployed more than $1.7 billion in customer-focused capital and are on track to invest more than $3.4 billion this year. Remain committed to our 5% to 7% annual average adjusted EPS 1 growth guidance through 2027 and 7% to 8% forecasted rate base growth through 2029. 'The second quarter of 2025 marks our fourth consecutive quarter of meaningful earnings increases, which can be attributed in large part to strong growth and favourable weather in Florida,' says Scott Balfour, President and CEO of Emera Inc. 'We continue to make essential investments across our operating companies to enhance reliability, storm harden our infrastructure and support economic and customer growth in the communities we serve. The continued need for this type of capital investment remains the fundamental driver of our 7% to 8% rate base growth expectations.' Q2 2025 Financial Results Q2 2025 adjusted net income 1 was $236 million, or $0.79 per common share, compared with $151 million, or $0.53 per common share, in Q2 2024. The increase was primarily due to increased earnings at Tampa Electric ('TEC'), Emera Energy Services ('EES'), and New Mexico Gas Company ('NMGC'); and lower corporate costs. These were partially offset by lower earnings at Nova Scotia Power ('NSPI') and decreased earnings due to the sale of Emera's equity interest in the Labrador Island Link ('LIL') in Q2 2024. Q2 2025 reported net income was $135 million, or $0.45 per common share, compared with net income of $129 million, or $0.45 per common share, in Q2 2024. Primarily driven by decreased MTM loss, after-tax, and higher earnings at TEC, partially offset by the $107 million gain, after tax and transaction costs, on the sale of Emera's equity interest in LIL in Q2 2024 and the $72 million in charges after-tax, primarily impairment, related to the pending sale of NMGC recognized in Q2 2025. Year-to-date Financial Results Year-to-date adjusted net income 1 was $615 million or $2.07 per common share, compared with $367 million or $1.28 per common share year-to-date in 2024. Year-to-date adjusted net income 1 increased $248 million primarily due to increased earnings at TEC, NSPI, EES, and NMGC; and lower corporate costs. These were partially offset by decreased earnings due to the sale of Emera's equity interest in LIL in Q2 2024. Year-to-date reported net income was $718 million or $2.41 per common share, compared with net income of $336 million or $1.17 per common share, year-to-date in 2024. Year-to-date reported net income included a $175 million MTM gain, after-tax, compared to a $138 million MTM loss, after-tax in 2024, and $72 million in charges related to the pending sale of NMGC, after-tax. Year-to-date reported income for 2024 included a $107 million gain, after tax and transaction costs, on the sale of Emera's equity interest in LIL in Q2 2024. The translation impact of a weaker CAD on USD earnings increased adjusted net income by $1 million in Q2 2025 and $15 million year-to-date compared to the same periods in 2024 and increased reported net income by $32 million in Q2 2025 and $62 million year-to-date compared to the same periods in 2024. Impacts of the changes in the translation of the CAD include the impacts of Corporate FX hedges used to mitigate translation risk of USD earnings in the Other segment. Segment Results and Non-GAAP Reconciliation For the Three months ended June 30 Six months ended June 30 millions of Canadian dollars (except per share amounts) 2025 2024 2025 2024 Adjusted net income 1,2 Florida Electric Utility $ 260 $ 187 424 272 Canadian Electric Utilities 17 42 138 129 Gas Utilities and Infrastructure 48 44 168 142 Other Electric Utilities 12 8 12 17 Other 3 (101) (130) (127) (193) Adjusted net income 1,2 $ 236 $ 151 615 367 Charges related to the pending sale of NMGC, after-tax 4,5 (72) - (72) - Gain on sale of LIL, after-tax 6 - 107 - 107 MTM (loss) gain, after-tax 7 (29) (129) 175 (138) Net income attributable to common shareholders $ 135 $ 129 718 336 EPS (basic) $ 0.45 $ 0.45 2.41 1.17 Adjusted EPS (basic) 1,2 $ 0.79 $ 0.53 2.07 1.28 1 See 'Non-GAAP Financial Measures and Ratios' noted below. 2 Excludes the charges related to the pending sale of NMGC, after-tax, gain on sale of LIL, after-tax, and the effect of after-tax MTM adjustments. 3 Higher earnings primarily due to higher contributions from EES, decreased operating, maintenance and general expenses ('OM&G'), and higher income tax recovery. These are partially offset by increased interest expense. 4 Represents $71 million in non-cash impairment charges, after-tax, and $1 million in transaction costs, after-tax for the three and six months ended June 30, 2025. 5 Net of income tax recovery of $5 million for the three and six months ended June 30, 2025. 6 Net of income tax expense of $75 million for the three and six months ended June 30, 2024. 7 Net of income tax recovery of $13 million for the three months ended June 30, 2025 (2024 – $52 million recovery) and $71 million income tax expense for the six months ended June 30, 2025 (2024 – $56 million recovery). Expand Consolidated Financial Review The following table highlights significant changes in adjusted net income attributable to common shareholders from 2024 to 2025. For the Three months ended Six months ended millions of Canadian dollars June 30 June 30 Adjusted net income – 2024 1,2 $ 151 $ 367 Operating Unit Performance Increased earnings at TEC due to higher revenue from new base rates, favourable weather, and customer growth, partially offset by increased income tax expense and higher depreciation. Year-over-year increase also due to the impact of a weaker CAD 73 152 Increased earnings at EES quarter-over-quarter due to lower transport costs and favourable hedge settlements related to EES' storage positions. Year-over-year increased due to favourable weather and resulting market conditions (higher natural gas prices and increased volatility) 10 34 Increased earnings at NMGC due to higher revenue from new base rates. Year-over-year increase also due to the impact of a weaker CAD 7 26 Decreased income from equity investments due to the sale of LIL in Q2 2024 (11) (28) Decreased earnings quarter-over-quarter at NSPI due to increased OM&G primarily driven by costs related to the cybersecurity incident and higher depreciation, partially offset by increased sales volumes. Increased earnings year-over-year due to investment tax credits ("ITCs") related to clean technology investments and increased sales volumes primarily driven by favourable weather, partially offset by higher depreciation and higher OM&G primarily driven by costs related to the cybersecurity incident (12) 41 Corporate Decreased OM&G primarily due to the timing of the recognition on long term compensation expense and related hedges 6 24 Increased income tax recovery due to decreased deferred income tax asset valuation allowance due to utilization of tax loss carryforwards 6 7 Increased interest expense primarily due to increased total debt, partially offset by lower interest rates (2) (7) Other Variances 8 (1) Adjusted net income – 2025 1,2 $ 236 $ 615 1 See 'Non-GAAP Financial Measures and Ratios' noted below and 'Segment Results and Non-GAAP Reconciliation" for reconciliation to nearest GAAP measure. 2 Excludes the charges related to the pending sale of NMGC, after-tax, gain on sale of LIL, after-tax , and the effect of after-tax MTM adjustments. Expand 1 Non-GAAP Financial Measures and Ratios Emera uses financial measures that do not have standardized meaning under USGAAP and may not be comparable to similar measures presented by other entities. Emera calculates the non-GAAP measures and ratios by adjusting certain GAAP measures for specific items. Management believes excluding these items better distinguishes the ongoing operations of the business. For further information on the non-GAAP financial measure, adjusted net income, and the non-GAAP ratio, adjusted EPS – basic, refer to the "Non-GAAP Financial Measures and Ratios" section of Emera's Q2 2025 MD&A which is incorporated herein by reference and can be found on SEDAR+ at Reconciliation to the nearest GAAP measure is included in 'Segment Results and Non-GAAP Reconciliation' above. Forward-Looking Information This news release contains forward-looking information or forward-looking statements within the meaning of applicable securities laws (collectively, 'forward-looking information'), including without limitation, statements about the Company's expectations regarding future growth, including expectations about 7% to 8% rate base growth, the nature and timing of future capital investments, results of operations, performance, the expected timing and outcome of the pending sale of NMGC, and business prospects and opportunities. By its nature, forward-looking information requires Emera to make assumptions and is subject to inherent risks and uncertainties. These statements reflect Emera management's current beliefs and are based on information currently available to Emera management. There is a risk that predictions, forecasts, conclusions and projections that constitute forward-looking information will not prove to be accurate, that Emera's assumptions may not be correct and that actual results may differ materially from those expressed or implied by such forward-looking information. Additional detailed information about these assumptions, risks and uncertainties is included in Emera's securities regulatory filings, including under the heading 'Enterprise Risk and Risk Management' in Emera's annual Management's Discussion and Analysis, and under the heading 'Principal Financial Risks and Uncertainties' in the notes to Emera's annual and interim financial statements, which can be found on SEDAR+ at or on EDGAR at The forward-looking information in this news release is made only as of the date of thereof, and Emera disclaims any intention or obligation to update or revise any forward-looking information. Teleconference Call The company will be hosting a teleconference today, Friday, August 8, at 9:30 a.m. Atlantic (8:30 a.m. Eastern) to discuss the Q2 2025 financial results. Analysts and other interested parties in North America are invited to participate by dialing 1-800-717-1738. International parties are invited to participate by dialing 1-289-514-5100. Participants should dial in at least 10 minutes prior to the start of the call. No pass code is required. A live and archived audio webcast of the teleconference will be available on the Company's website, A replay of the teleconference will be available on the Company's website two hours after the conclusion of the call. About Emera Emera (TSX/NYSE: EMA) is a leading North American provider of energy services headquartered in Halifax, Nova Scotia, with investments in regulated electric and natural gas utilities, and related businesses and assets. The Emera family of companies delivers safe, reliable energy to approximately 2.6 million customers in the United States, Canada and the Caribbean. Our team of 7,600 employees is committed to our purpose of energizing modern life and delivering a cleaner energy future for all. Emera's common and preferred shares are listed and trade on the Toronto Stock Exchange and its common shares are listed and trade on the New York Stock Exchange. Additional information can be accessed at on SEDAR+ at and on EDGAR at
